Stoke Therapeutics (STOK) Income towards Parent Company: 2022-2025
Historic Income towards Parent Company for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$38.3 million.
- Stoke Therapeutics' Income towards Parent Company fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
- Latest data reveals that Stoke Therapeutics reported Income towards Parent Company of -$38.3 million as of Q3 2025, which was down 63.30% from -$23.5 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Income towards Parent Company ranged from a high of $112.9 million in Q1 2025 and a low of -$38.3 million during Q3 2025.
- Its 3-year average for Income towards Parent Company is -$13.0 million, with a median of -$25.7 million in 2024.
- Data for Stoke Therapeutics' Income towards Parent Company shows a peak YoY increase of 527.99% (in 2025) and a maximum YoY decrease of 45.09% (in 2025) over the last 5 years.
- Stoke Therapeutics' Income towards Parent Company (Quarterly) stood at -$25.7 million in 2022, then decreased by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plummeted by 45.09% to -$38.3 million in 2025.
- Its Income towards Parent Company was -$38.3 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $112.9 million in Q1 2025.